Precertification process change for certain infusion therapy drugs

As part of our continuing efforts to improve the quality and affordability of health care, we are making important changes to the precertification process for our members who receive alglucerase (Ceredase®), imiglucerase (Cerezyme®), velaglucerase alfa (VPRIV®), or eculizumab (Soliris®). Effective January 1, 2012, all precertification requests for these drugs will be reviewed to determine if members are receiving them in the setting that is cost-effective, safe, and clinically appropriate for their medical needs.

Read more about this change in the December edition of Partners in Health UpdateSM.